Search
Dihydrostreptomycin
go.drugbank.com/drugs/DB11512ApprovedVet approvedWithdrawnDihydrostreptomycin is an aminoglycoside antibiotic. In humans, the use of dihydrostreptomycin has been associated with ototoxicity.
Synonyms: N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-a-L-glucopyranosyl]-3-C-(hydroxymethyl)-a-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine, N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-α-L-glucopyranosyl]-3-C-(hydroxymethyl)-α-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidineMagnesium orotate
go.drugbank.com/drugs/DB13786ExperimentalMagnesium orotate is a magnesium salt of orotic acid and is poorly soluble in water. It is a source of magnesium and is used as a mineral supplement to treat Mg deficiency. … It also exhibits antioxidant properties, since it is a key intermediate in the biosynthetic pathway of pyrimidines that promotes the synthesis of enzymes which act as free radical scavengers.
GB-13
go.drugbank.com/drugs/DB18387ExperimentalGB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.
Pamiparib
go.drugbank.com/drugs/DB14769InvestigationalPamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression
Dimenoxadol
go.drugbank.com/drugs/DB01461ExperimentalIllicitIn the United States it is classified as a Schedule I controlled drug. … Dimenoxadol is an opioid analgesic which produces typical opioid effects such as analgesia and sedation. It is structurally similar to methadone and is a benzilic acid derivative.
Orbifloxacin
go.drugbank.com/drugs/DB11443ExperimentalVet approvedOrbifloxacin is a fluoroquinolone antibiotic. It is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.
AZD0947
go.drugbank.com/drugs/DB04848ExperimentalAs of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline. … AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.
Candoxatrilat
go.drugbank.com/drugs/DB11623ExperimentalA potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro-1H-inden-5-yl ester prodrug in the treatment of chronic heart failure.